Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms MEASURE 4
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Feb 2022 Results of post-hoc pooled analysis of 3 secukinumab studies (MEASURE 2,-3 &-4) assessing -term NSAID-sparing effect of secukinumab over 4 years in patients with r-axSpA, published in the Rheumatology International.
    • 05 Jun 2021 Results of post-hoc pooled analysis of 6 studies (MEASURE 1-5 & PREVENT) presented at the 22nd Annual Congress of the European League Against Rheumatism.
    • 15 Mar 2021 Results of post-hoc pooled analysis from four clinical studies: NCT01358175, NCT01649375, NCT02008916 and NCT02159053 published in The Journal of Rheumatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top